·Î±×ÀÎ ¸¶ÀÌÆäÀÌÁö ÀÌ¿ë¾È³» °í°´¼¾ÅÍ ¼­ºñ½º¾È³»
ä¿ëÁ¤º¸µî·Ï À̷¼­µî·Ï
ä¿ëÁ¤º¸ ÇìµåÇåÆà ÀÎÀçÁ¤º¸ Ä¿¹Â´ÏƼ °í°´¼¾ÅÍ ¼îÇθô
±â¾÷ȸ¿ø¼­ºñ½º°³ÀÎȸ¿ø¼­ºñ½º
Àαâ°Ë»ö¾î : ¿µ¾÷ ¸¶ÄÉÆà ÀÓ»ó ¿¬±¸ Ç°Áú°ü¸® ÀλçÃѹ« »ý»êÁ÷ ¾à»ç ÀÎÇã°¡ °£È£»ç
ȸ¿ø°¡ÀÔ¾ÆÀ̵ð/ºñ¹Ð¹øȣã±â
ä¿ëÁ¤º¸
Àüüä¿ëÁ¤º¸
Áö¿ªº°
Á÷Á¾º°
¿ª¼¼±Çº°
±Þ¿©º°
»ó¼¼°Ë»ö
±Ù¹«Çüź°
ÃßÈÄÇùÀÇ
ÀÎÅÏÁ÷
Á¤±ÔÁ÷
°è¾àÁ÷
º´¿ªÆ¯·Ê
ÇÁ¸®·£¼­
Çзº°
ÃʵîÇб³
ÁßÇб³
°íµîÇб³
´ëÇÐ(2~3³â) ÀçÇÐ
´ëÇÐ(2~3³â) Á¹¾÷
´ëÇÐ(4³â) ÀçÇÐ
´ëÇÐ(4³â) Á¹¾÷
´ëÇпø(¼®»ç) Á¹¾÷
´ëÇпø(¹Ú»ç) Á¹¾÷
°æ·Âº°
½ÅÀÔ
1³âÀÌ»ó~3³â¹Ì¸¸
3³âÀÌ»ó~5³â¹Ì¸¸
5³âÀÌ»ó~10³â¹Ì¸¸
10³âÀÌ»ó
 
 
 
Á÷Á¾
Áö¿ª ¼ºº° ÇзÂ
°æ·Â Å°¿öµå
(ÁÖ)¹ÙÀ̳ؽº
ÀÎõ(¼Ûµµ) PV(ÄɹÌÄ®ÆÄÆ®) °æ
µî·ÏÀϼø | ¼öÁ¤Àϼø | ¸¶°¨Àϼø | Á¶È¸¼ø | °æ·Â¡è | °æ·Â¡é
  ȸ»ç¸í ä¿ëÁ¤º¸Á¦¸ñ ¸ðÁýÁ÷Á¾ °æ·Â ¸¶°¨ÀÏ ¼öÁ¤ÀÏ
(ÁÖ)Å¥¶óƼ½º ÀÓ»óÀÎÇã°¡ÆÀ PV Á¤±ÔÁ÷ ¸ðÁý
¼­¿ï ¼­Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷
PL/PV/PMS/MD 5³â¡è ä¿ë½Ã 06.22
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ [Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼­¿ï ¼­Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷
PL/PV/PMS/MD 5³â¡è ä¿ë½Ã 05.18
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ [Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼­¿ï ¼­Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷
PL/PV/PMS/MD 5³â¡è ä¿ë½Ã 05.18
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ [Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼­¿ï ¼­Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷
PL/PV/PMS/MD 5³â¡è ä¿ë½Ã 05.12
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ [Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼­¿ï ¼­Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷
PL/PV/PMS/MD 5³â¡è ä¿ë½Ã 05.08
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ [Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼­¿ï ¼­Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷
PL/PV/PMS/MD 5³â¡è ä¿ë½Ã 04.27
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ [Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼­¿ï ¼­Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷
PL/PV/PMS/MD 5³â¡è ä¿ë½Ã 04.27
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ [Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼­¿ï ¼­Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷
PL/PV/PMS/MD 5³â¡è ä¿ë½Ã 04.22
Çö´ë¾àÇ°ÁÖ½Äȸ»ç [Çö´ë¾àÇ°] Medical Writer ä¿ë
¼­¿ï °­³²±¸ | ´ëÇÐ(4³â) Á¹¾÷
PL/PV/PMS/MD 3³â¡è ä¿ë½Ã 07.20
Çѱ¹ÇÁ¶óÀÓÁ¦¾à Á¦¾à°³¹ßºÎ PVÆÀ ½ÅÀÔ ¹× °æ·ÂÁ÷ ä¿ë
¼­¿ï ¿µµîÆ÷±¸ | ´ëÇÐ(4³â) Á¹¾÷
PL/PV/PMS/MD 2³â¡è ä¿ë½Ã 03.26
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) [PPC Korea] PV Associate ä¿ë
¼­¿ï °­³²±¸ | ´ëÇÐ(4³â) Á¹¾÷
PL/PV/PMS/MD 2³â¡è ä¿ë½Ã 01.29
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) [PPC Korea] PV Associate ä¿ë
¼­¿ï °­³²±¸ | ´ëÇÐ(4³â) Á¹¾÷
PL/PV/PMS/MD 2³â¡è ä¿ë½Ã 04.23
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼­ºñ½º [LSK global PS] SP / ERA / PL ä¿ë
¼­¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷
PL/PV/PMS/MD 1³â¡è ä¿ë½Ã 12.02
(ÁÖ)È޿½º Huons±×·ì ÀÓ»ó±âȹ½Ç ÀǾàÇ°¾ÈÀü°ü¸® °æ·ÂÁ÷ ä¿ë
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷
PL/PV/PMS/MD 1³â¡è ä¿ë½Ã 06.21
PRA Health Sciences [PRA Health Sciences] CRA I, II, III, Drug Safety Associ
¼­¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ
CRA/ÀÓ»óPM/CRM 1³â¡è ä¿ë½Ã 06.28
1   2
°³ÀÎÁ¤º¸Ã³¸®¹æħ | ȸ¿ø¾à°ü | °í°´Áö¿ø¼¾ÅÍ | Á¦ÈÞ ¹× ±¤°í¹®ÀÇ | ´ÙÀÌ·ºÆ®°áÁ¦